Kaur Navneet, Garg Ravinder, Tapasvi Chaitanya, Goyal Gitanjali
Department of Biochemistry, Guru Gobind Singh Medical College and Hospital, Baba Farid University of Health Sciences, Faridkot 151203, Punjab, India.
Department of Medicine, Guru Gobind Singh Medical College and Hospital, Baba Farid University of Health Sciences, Faridkot 151203, Punjab, India.
World J Virol. 2025 Jun 25;14(2):101976. doi: 10.5501/wjv.v14.i2.101976.
Hepatitis C virus (HCV) infection process of progression encompasses multiple stages, commencing with inflammation and culminating in hepatocellular cancer. Numerous invasive and non-invasive procedures exist for diagnosing chronic HCV infection. Though beneficial, invasive procedures can cause morbidity and inadequate representation of the overall degree of fibrosis. Due to these reasons, non-invasive liver fibrosis biomarkers are becoming more prevalent to diagnose and track liver fibrosis without a liver biopsy. These biomarkers can detect liver fibrosis early, improving treatment and preventing cirrhosis and liver failure. Micro ribonucleic acid (MiRNA) dysregulation causes and worsens several diseases including liver disease. MiRNAs can facilitate the diagnosis of liver fibrosis and serve as a predictive tool to enhance patient care by minimizing invasive procedures and enabling more efficient and prompt therapy.
To investigate the diagnostic effectiveness of several miRNAs (miRNA-122, miRNA-21, miRNA-199a, miRNA-155) in assessing the liver fibrosis severity in untreated HCV patients from the Indian Punjab population. We seek to identify the intricate diagnostic relationship of miRNAs with the extent of fibrosis among individuals with HCV.
We considered 100 persons determined as HCV infected by a quantitative Real-Time Polymerase Chain Reaction examination. We employed statistical as well as probabilistic tools to ascertain the diagnostic validity of miRNAs for determining the liver fibrosis stages. We employed Bayesian Networks, to introduce a unique diagnostic paradigm for miRNAs that can be adopted as benchmark to evaluate the liver fibrosis severity in HCV cases.
We found that miRNAs (miR-122, miR-155 and miR-21) showed significant upregulation when compared with control and according to severity of fibrosis ( ≤ 0.05). The area under the curve for miR-122, miR-155, miR-21 and miR-199a in HCV group in relation to Liver Stiffness Measurement was calculated as 0.889, 0.933, 0.912 and 0.035 respectively. MiR-199a was downregulated according to degree of fibrosis.
Depending on the diagnostic accuracy, we have concluded that miR-122, miR-155 and miR-21 are reliable markers to detect fibrosis in Hepatitis C patients.
丙型肝炎病毒（HCV）感染的进展过程包括多个阶段，始于炎症，最终发展为肝细胞癌。存在多种侵入性和非侵入性方法用于诊断慢性HCV感染。尽管侵入性方法有益，但它们可能导致发病率增加，并且不能充分反映纤维化的整体程度。由于这些原因，非侵入性肝纤维化生物标志物在无需肝活检的情况下诊断和跟踪肝纤维化方面变得越来越普遍。这些生物标志物可以早期检测肝纤维化，改善治疗并预防肝硬化和肝衰竭。微小核糖核酸（MiRNA）失调会引发并加重包括肝病在内的多种疾病。MiRNA可以促进肝纤维化的诊断，并作为一种预测工具，通过减少侵入性操作并实现更高效、及时的治疗来提高患者护理水平。
研究几种MiRNA（miRNA-122、miRNA-21、miRNA-199a、miRNA-155）在评估印度旁遮普邦未治疗的HCV患者肝纤维化严重程度方面的诊断有效性。我们试图确定MiRNA与HCV感染者纤维化程度之间复杂的诊断关系。
我们纳入了100名经定量实时聚合酶链反应检测确定为HCV感染的患者。我们使用统计和概率工具来确定MiRNA在确定肝纤维化阶段方面的诊断有效性。我们采用贝叶斯网络，为MiRNA引入一种独特诊断模式，可作为评估HCV病例肝纤维化严重程度的基准。
我们发现，与对照组相比，MiRNA（miR-122、miR-155和miR-21）根据纤维化严重程度显示出显著上调（≤0.05）。HCV组中miR-122、miR-155、miR-21和miR-199a相对于肝脏硬度测量的曲线下面积分别计算为0.889、0.933、0.912和0.035。miR-199a根据纤维化程度下调。
根据诊断准确性，我们得出结论，miR-122、miR-155和miR-21是检测丙型肝炎患者纤维化的可靠标志物。
